ArticleJournal of nanobiotechnology2025
In situ construction of heterojunctions to regulate the biodegradation behavior of copper carriers for tumor-specific cuproptosis-enhanced sono-immunotherapy.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Copper-based metal-organic frameworks: applications and prospects in cancer diagnosis and therapy.RSC advances · 2026Review
- Cuproptosis meets sonodynamics: a nanomedicine platform for multimodal cancer therapy.RSC advances · 2026Review
- Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment.Frontiers in immunology · 2026Review
- Sensitization strategy for sonodynamic therapy.Theranostics · 2026Review
- Cuproptosis-triggering nanomedicine boosts antitumor immunotherapy.Theranostics · 2026Review
- Copper-coordinated engineered nanoreactors with self-amplifying OJournal of nanobiotechnology · 2025Article
- Cu-doping site regulation in carbon dots for concurrent cuproptosis-like death anti-bacteria and osteogenesis of infected bone defects.Journal of nanobiotechnology · 2025Article
- Mechanism and application of copper-based nanomedicines in activating tumor immunity through oxidative stress modulation.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cuproptosis, a novel approach utilizing copper carriers to trigger programmed cell death, exhibits promise for enhancing traditional therapies and activating robust adaptive immune responses. However, the uncontrolled release of Cu ions risks triggering cuproptosis in healthy tissues, potentially causing irreversible damage. To address this, we report on the use of a Cu-MOF (copper metal-organic framework) protective layer to regulate the biodegradation of copper-based nanomaterials. In situ formation of Cu-MOF on Cu
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.